Cantuzumab ravtansine - Misplaced Pages

Chemical compound Pharmaceutical compound

Cantuzumab ravtansine
Monoclonal antibody

Type	Whole antibody
Source	Humanized (from mouse)
Target	MUC1
Clinical data
ATC code	none
Identifiers
CAS Number	868747-45-9
ChemSpider	none
UNII	RNQ8JQ4R9P
KEGG	D10454
(what is this?) (verify)

Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4). It uses a more hindered disulfide linkage than cantuzumab mertansine.

References

World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2). Archived from the original (PDF) on April 1, 2012.
Goldmacher VS, Singh R, Chittenden T, Kovtun Y (2013). "Linker technology and impact of linker design on ADC properties.". In Phillips GL (ed.). Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. New York: Springer. pp. 117–135 (131). ISBN 978-1-4614-5456-4.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab Amivantamab Ascrinvacumab Atezolizumab (+hyaluronidase) Balstilimab Botensilimab Cixutumumab Conatumumab Cosibelimab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Enoticumab Figitumumab Flanvotumab Ganitumab Glembatumumab vedotin Intetumumab Ipilimumab Iratumumab Istiratumab Icrucumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Nesvacumab Nivolumab Ofatumumab Olaratumab Panitumumab Patritumab Pembrolizumab Pritumumab Radretumab Ramucirumab Rilotumumab Robatumumab Seribantumab Sugemalimab Tarextumab Tisotumab vedotin Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab Bavituximab Brentuximab vedotin Carotuximab Cetuximab Derlotuximab biotin Dinutuximab Ecromeximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Cirmtuzumab Citatuzumab bogatox Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab Demcizumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Epcoritamab Etaracizumab Farletuzumab Ficlatuzumab Flotetuzumab Gemtuzumab ozogamicin Glofitamab Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab Milatuzumab Naxitamab Nimotuzumab Obinutuzumab Ocaratuzumab Odronextamab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine Sacituzumab govitecan Sibrotuzumab Simtuzumab Sofituzumab vedotin Tacatuzumab tetraxetan Tigatuzumab Trastuzumab (+deruxtecan / +emtansine) Tucotuzumab celmoleukin Vandortuzumab vedotin Vanucizumab Veltuzumab Vorsetuzumab mafodotin Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab
Chimeric + humanized	Depatuxizumab mafodotin Duvortuxizumab Ontuxizumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories:

See also

References